Skip to main content

Cefixime Pregnancy and Breastfeeding Warnings

Brand names: Suprax

Medically reviewed by Drugs.com. Last updated on Mar 19, 2024.

Cefixime Pregnancy Warnings

Use is recommended only if clearly needed and the benefit outweighs the risk.

US FDA pregnancy category: B

Animal studies have failed to reveal evidence of fetal harm or impaired fertility at doses up to 400 times the recommended human dose; however, there was increased incidence of abortion at levels reaching maternal toxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Cefixime Breastfeeding Warnings

Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes

Comments:
-The American Academy of Pediatrics considers other cephalosporins (e.g., cefadroxil, cefazolin) as compatible with breastfeeding.
-Maternal doses of cephalosporins have resulted in reports of neonatal diarrhea and thrush.

See references

References for pregnancy information

  1. (2002) "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

References for breastfeeding information

  1. (2002) "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
  4. Briggs GG, Freeman RK. (2015) "Drugs in Pregnancy and Lactation." Philadelphia, PA: Wolters Kluwer Health

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.